Humanin: the mitochondrial-derived peptide you have not heard of

Among the peptides circulating in the longevity and recovery scene, Humanin occupies a strange niche. It is genuinely fascinating from a basic-science angle — a 24-amino-acid peptide encoded inside the mitochondrial genome, signaling outward to the rest of the cell — and almost entirely uncharacterized in healthy human use. Its sister molecule MOTS-c gets most of the strength-peptide community's attention. Humanin is sitting one shelf back, waiting for either better human data or a vendor with marketing budget.

This post is an honest map of what we know, what we don't, and whether Humanin deserves a place in your peripheral awareness or your actual practice.

What Humanin is

Humanin was discovered in 2001 by Hashimoto and colleagues in Japan, while screening for genes that protect neurons against Alzheimer's-associated amyloid-beta toxicity. The peptide they isolated was unusual in several ways:

• It is encoded by a short open reading frame within the 16S ribosomal RNA gene of mitochondrial DNA — meaning it is a mitochondrial-derived peptide (MDP), produced from the small circular genome inside your mitochondria rather than from nuclear DNA
• It is 24 amino acids long in its mitochondrial form, with a slightly longer 21-amino-acid cytosolic form depending on translation site
• It acts as a signaling peptide, secreted from cells and binding to a heterotrimeric receptor complex on the cell surface (FPRL1, FPRL2, and an IL-6 family co-receptor)

Humanin sits in the same biological family as MOTS-c, SHLP1–6 (Small Humanin-Like Peptides), and other mitochondrial-derived peptides. The discovery of these molecules has reshaped how researchers think about mitochondria: not just as energy producers, but as endocrine organs sending signals to the rest of the body.

For the broader frame on mitochondrial-derived peptides in the strength-peptide space, see the MOTS-c pillar guide.

What the research suggests

The human evidence for Humanin is mostly observational and mechanistic. The clearest signals are:

Levels decline with age. Plasma Humanin concentrations drop substantially across the adult lifespan, with some studies showing 50–75% reductions between young adults and elderly subjects (Muzumdar et al., 2009, PLOS ONE; Yen et al., 2013, Aging). This pattern parallels MOTS-c and the general age-related decline in mitochondrial signaling.

Higher levels associate with metabolic health. Cross-sectional studies have found inverse correlations between circulating Humanin and markers of insulin resistance, visceral adiposity, and inflammation. Whether that's causal or downstream of better underlying mitochondrial function is unresolved.

Animal data on neuroprotection is consistent. In rodent models of Alzheimer's, stroke, and other neurological insults, exogenous Humanin and its synthetic analog HNG (S14G-Humanin) reduce neuronal death and improve functional outcomes. HNG is roughly 1,000-fold more potent than native Humanin and is the variant most studied in preclinical work.

Insulin sensitivity signal in animals. Acute administration of Humanin in rodents enhances glucose uptake and improves insulin sensitivity through both peripheral and central mechanisms. The effect is modest but reproducible.

Cardioprotection in ischemia-reperfusion models. Animal studies show Humanin pretreatment reduces infarct size in cardiac ischemia models, similar to other mitochondrial peptides like SS-31. For the comparable case on SS-31, see SS-31 / Elamipretide mitochondrial recovery.

What's missing is human interventional data in healthy people at any serious scale. The peptide has been administered to humans in small clinical contexts — but no large randomized trial has established a clinical effect at any defined dose in any defined population.

Humanin vs MOTS-c

These two get conflated. They are not interchangeable.

MOTS-c is closer to "ready for the strength-peptide community" because its mechanism connects to AMPK and exercise-like adaptations — a story that maps to how lifters and biohackers already think. Humanin's strongest data is in neuroprotection, which is harder to feel and harder to dose toward.

Why Humanin is hard to use right now

Several practical problems sit between the promising biology and any real-world use:

Synthesis quality is inconsistent. Humanin is short enough to synthesize, but the research-chemical market for it is thin. Few vendors carry it; fewer still publish credible third-party COAs. Identity, purity, and potency are harder to verify than for established peptides. For the framework on evaluating that, see vendor due diligence checklist and reading a COA, worked example.

Dosing is undefined for healthy adults. Animal effective doses translate poorly to humans. The HNG analog used in much animal work is more potent than native Humanin but not what's typically sold. Community-suggested protocols (often in the 1–5 mg subcutaneous range) are essentially extrapolations without human dose-response data to anchor them.

Stability and bioavailability concerns. Like other mid-length peptides, Humanin has poor oral bioavailability and uncertain subcutaneous absorption kinetics. The half-life from injection sites and the resulting plasma exposure are not well-published.

No clear "what will I feel" answer. Unlike GH secretagogues (sleep, hunger, water retention) or BPC-157 (pain reduction at injury sites), Humanin's effects in animal models — modest insulin sensitization, neuroprotection against future stressors — are not things a healthy user can perceive in real time. That makes it hard to know whether the product you bought is working, working at the wrong dose, or doing nothing.

Who might still consider Humanin

Given the above, this is a peptide for a narrow set of users:

Longevity-focused biohackers comfortable with experimental compounds. If you already use other mitochondrial peptides (MOTS-c, SS-31) and are willing to invest in something with thinner data on the bet that the biology pans out, Humanin is a defensible addition — provided sourcing quality is verifiable.

People with a personal mitochondrial-disease context. Outside the scope of recreational use, but worth noting that some patients with mitochondrial disorders have explored Humanin and related peptides as adjuncts to other supportive care. This sits firmly in the medically-supervised category.

Researchers and self-experimenters tracking specific biomarkers. If you're already doing fasting insulin, HOMA-IR, inflammatory markers, and other tracking, Humanin becomes more interpretable. Without that infrastructure, you're guessing.

For people focused on strength, hypertrophy, or recovery, Humanin is the wrong tool. The mechanism doesn't connect to those outcomes, and the time and budget are better spent on peptides with better data and clearer endpoints — BPC-157, TB-500, Ipamorelin, MOTS-c.

What to watch for

The peptide field around mitochondrial-derived peptides is moving. Specifically:

• HNG and other synthetic analogs may eventually become commercially available with cleaner pharmacology than native Humanin
• MOTS-c is further along and may serve as the regulatory and commercial pathfinder for this whole class
• Aging biomarker panels that include Humanin and MDPs are starting to appear in research contexts, which will eventually allow individualized dose-response work

If you're tracking longevity peptides as a category, Humanin is on the watch list — not the shopping list.

The honest framing

Humanin is a real molecule with real biology. The pre-clinical data is interesting and the basic-science story is one of the more exciting threads in mitochondrial signaling. The peptide itself, as a thing you can buy and inject today, is not where the action is — sourcing is uncertain, dosing is undefined, and the effects are hard to feel or measure.

If you're going to allocate budget and attention to the mitochondrial-peptide space right now, MOTS-c is the better-developed entry point. Humanin is worth knowing about. It's not yet worth using.

Related reading

• Mitochondrial health and MOTS-c longevity
• SS-31 / Elamipretide mitochondrial recovery
• MOTS-c research evidence
• MOTS-c mechanism
• Reading a COA: worked example